Significant and durable clinical benefit from trastuzumab in 2 patients withHER2-amplified salivary gland cancer and a review of the literature

Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients

(2016) Kuninori Otsuka et al.   ANNALS OF SURGICAL ONCOLOGY

Genetic alterations in salivary gland cancers

(2016) Linda X. Yin et al.   CANCER

Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations

(2016) K. Wang et al.   CLINICAL CANCER RESEARCH

Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer

(2016) M. G. Dalin et al.   CLINICAL CANCER RESEARCH

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor Palbociclib

(2016) Mark A. Dickson et al.   JAMA Oncology

Molecular Characterization of Apocrine Salivary Duct Carcinoma

(2015) Simion I. Chiosea et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations

(2015) Peter P. Luk et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Dual gain of HER2 and EGFR gene copy numbers impacts the prognosis of carcinoma ex pleomorphic adenoma

(2015) Toshimitsu Nishijima et al.   HUMAN PATHOLOGY

Outcome analysis of 215 patients with parotid gland tumors: a retrospective cohort analysis

(2015) Boban M. Erovic et al.   Journal of Otolaryngology-Head & Neck Surgery

Genomic landscape of salivary gland tumors

(2015) Shumei Kato et al.   Oncotarget

Clinical outcome of patients with carcinoma ex pleomorphic adenoma of the parotid gland: A comparative study from a single tertiary center

(2014) Chwee Ming Lim et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma

(2014) Tatsuo Masubuchi et al.   International Journal of Clinical Oncology

High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma

(2014) Bo Mi Ku et al.   Journal of Translational Medicine

Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers

(2014) Göran Stenman et al.   ORAL ONCOLOGY

Recent advances in the diagnostic pathology of salivary carcinomas

(2014) Roderick H. W. Simpson et al.   VIRCHOWS ARCHIV

Human epidermal receptor 2-amplified salivary duct carcinoma: Regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment

(2013) Gerald S. Falchook et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database

(2013) Vijayvel Jayaprakash et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma

(2013) Mark A. Dickson et al.   JOURNAL OF CLINICAL ONCOLOGY

Salivary Duct Carcinoma of the Parotid Gland: Is Adjuvant HER-2–Targeted Therapy Required?

(2013) Jong Sil Lee et al.   JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

Trastuzumab for the Treatment of Salivary Duct Carcinoma

(2013) S. A. Limaye et al.   ONCOLOGIST

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

(2012) J. P. Leonard et al.   BLOOD

Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment

(2012) V. Nardi et al.   CLINICAL CANCER RESEARCH

Recurrent Salivary Gland Cancer

(2012) M. Boyd Gillespie et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes*

(2012) Silvana Di Palma et al.   HISTOPATHOLOGY

HER-2/neu gene amplification in carcinoma ex pleomorphic adenoma in relation to progression and prognosis: a chromogenic in-situ hybridization study

(2012) Kazuki Hashimoto et al.   HISTOPATHOLOGY

Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas

(2011) Till Sebastian Clauditz et al.   PATHOLOGY

Histologic Grading and Prognostic Biomarkers in Salivary Gland Carcinomas

(2010) Raja R. Seethala   ADVANCES IN ANATOMIC PATHOLOGY

p16 Positive Oropharyngeal Squamous Cell Carcinoma:An Entity With a Favorable Prognosis Regardless of Tumor HPV Status

(2010) James S. Lewis et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Genetic and Expression Analysis of HER-2 and EGFR Genes in Salivary Duct Carcinoma: Empirical and Therapeutic Significance

(2010) M. D. Williams et al.   CLINICAL CANCER RESEARCH

Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine

(2010) Elad Sharon et al.   Head and Neck Optical Diagnostics Society

Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)

(2009) Laura D. Locati et al.   ORAL ONCOLOGY

Carcinoma ex pleomorphic adenoma of the parotid gland. Study and implications for diagnostics and therapy

(2008) Jan-Christoffer Lüers et al.   ACTA ONCOLOGICA

Carcinoma ex pleomorphic adenoma: Diagnostic difficulty and outcome

(2008) Peter Zbären et al.   OTOLARYNGOLOGY-HEAD AND NECK SURGERY

Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy

(2007) Aleix Prat et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK